New Treatment Paradigms Monograph

New Treatment Paradigms in Second-line Therapy for Pancreatic Cancer
New Treatment Paradigms in Second-line Therapy for Pancreatic Cancer
CME, CPE
Tanios Bekaii-Saab, MD, FACP
Release Date: June 01, 2016
Expiration Date: June 01, 2017
This activity will describe treatment options in the second-line setting for patients with advanced (metastatic) pancreatic cancer. Dr. Tanios Bekaii-Saab explains new treatment paradigms in second-line therapy given the approval of nanoliposomal irinotecan, including therapeutic selection based on prior therapy and toxicities of currently available agents.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Merrimack Pharmaceuticals, Inc.
View Only, CE ExpiredView Only, No Credit
 

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved